Obiettivo
The problem: Blood glucose levels in critically ill patients require close attention by the physicians and nurses in the intensive care units (ICU) because these patients spontaneously develop hyperglycaemia and increased variability of blood glucose. Unexpected drops in blood glucose are frequently caused by over-administration of insulin – exposing patient´s lives to dangerous hypoglycaemic episodes. These incidents increase the length of stay in ICUs and each bed day in an ICU has large direct costs around €1425.
The solution: GlucoSet is a novel dome-shaped hydrogel sensor that changes its volume and consequently its optical path length in the presence of glucose. The hydrogel tip is built at the end of thin optical fibres (125 µm), which enables GlucoSet to be the only technology small enough to pass through wrist arterial catheters, installed in most (up to 94%) ICU patients, without disturbing the blood pressure monitoring. GlucoSet has the potential to be the first real-time monitoring system for measuring glycaemia from arterial blood, which offer several advantages over central venous access such as higher accuracy and sensibility, less risk of interference from infusions, and much more convenient use.
The market: Critical care services face increasing demand worldwide – more particularly in the EU. With continuous increase in aging population in Europe along with life style related diseases, the number of critically ill patients needing accurate glucose monitoring in the ICUs will certainly rise. GlucoSet AS estimates a total market size of € 980 million per year for the intravascular continuous glucose monitoring, being the company in a strong position to exploit an addressable turnover exceeding € 115 million, five years after market introduction. Equally important, we estimate that the GlucoSet will allow savings of at least €2000 per patient in ICUs.
Campo scientifico
- medical and health sciencesclinical medicinecritical care medicine
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- medical and health sciencesmedical biotechnologytissue engineeringartificial pancreascontinuous glucose monitors
- natural sciencesphysical sciencesopticsfibre optics
Programma(i)
- H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
- H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
- H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-1-2016-2017
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
7037 Oslo
Norvegia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.